Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Ipsen
Yale University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Seagen Inc.
National Cancer Institute (NCI)
Baylor College of Medicine
Bristol-Myers Squibb
University Hospital, Akershus
Astellas Pharma Inc
University of Michigan Rogel Cancer Center
Beijing Tsinghua Chang Gung Hospital
Ottawa Hospital Research Institute
National Cancer Institute (NCI)
Incyte Corporation
Hoffmann-La Roche
Hoffmann-La Roche
Gilead Sciences
Bristol-Myers Squibb
Leap Therapeutics, Inc.
Bristol-Myers Squibb
NuCana plc
Institut Bergonié
BeiGene
Bristol-Myers Squibb
GERCOR - Multidisciplinary Oncology Cooperative Group
BeiGene
AIDS Malignancy Consortium
Merck Sharp & Dohme LLC
Gilead Sciences
Mayo Clinic
AIDS Malignancy Consortium
UNC Lineberger Comprehensive Cancer Center
University of Chicago
NRG Oncology
University of Chicago
Imugene Limited
National Cancer Institute (NCI)
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Alliance for Clinical Trials in Oncology
Hospital of Stomatology, Wuhan University
GlaxoSmithKline
Dana-Farber Cancer Institute